Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33% [Yahoo! Finance]
Corbus Pharmaceuticals (CRBP) had its price target raised by Oppenheimer Holdings, Inc. from $53.00 to $57.00. They now have an "outperform" rating on the stock.
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update